?? T Cell Cancer Immunotherapy

?? T Cell Cancer Immunotherapy: Evidence-Based Perspectives for Clinical Translation sets out and critically discusses the current clinical and relevant preclinical ?? T cell immunotherapy landscape.
In five chapters, field experts discuss the challenges facing ?? T cell oncoimmunotherapy, propose solutions, and map next steps.

Particular attention is given to summarizing our understanding of the complex, translationally relevant human ?? T cell biology, the evidence basis for designing ?? T cell combination trials and data-driven perspectives on what is known-and what isn't-about ?? T cell therapeutic persistence. Various perspectives are provided on how issues of cytotoxic effector function, functional exhaustion, and cytokine addiction can be mitigated using gene engineering.
A chapter is dedicated to the systematic review of all ?? T cell immunotherapy trials to date, and the cell therapy products that were used in these trials. The final chapter discusses allograft persistence-enhancement techniques in the context of ?? T cell therapy, covering lymphodepleting chemotherapy and synthetic stealth engineering.

?? T Cell Cancer Immunotherapy: Evidence-Based Perspectives for Clinical Translation gives an updated and comprehensive insight into the current state of ??T cell immunotherapy, which is of interest to existing translational ?? T cell specialists, the proliferating range of academic scientists and commercial scientists entering the field, as well as clinicians who may encounter ?? T cell immunotherapy in the clinic, or are wishing to familiarize themselves with noncanonical lymphocyte immunotherapy.

• Summarizes the cutting edge of oncology-relevant ?? T cell immunobiology
• Lays out clinical successes and failures to date
• Addresses the possible advantage of combining ?? T cell-based immunotherapy with conventional chemotherapy or checkpoint blockers
• Provides an up-to-date and well-rounded discussion of a translationally, commercially, and scientifically relevant field